Search
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsTiamulin
go.drugbank.com/drugs/DB11468ExperimentalVet approvedTiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs and poultry.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2E1 InhibitorsProducts: PF TIAMULIN PREMIX 10% W/W POWDERMetoclopramide
go.drugbank.com/drugs/DB01233ApprovedInvestigationalIt can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. … It is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]
Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein substratesProducts: PP-METOCLOPRAMIDE TABLET, Mar-metoclopramideNeostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Products: NEOSTIGMINA METILSULFATO SOLUCION INYECTABLE DE 0.5 MG / 1 ML.Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. … [A189168] To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsNadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnLow molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Products: FRAXIPARINE 0.3ML DUO, FRAXIPARINE 0.3ML INJ 7,500 IC U AXAElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is market...
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigationalBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigationalGlyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin se...
Synonyms: 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylureaMixtures: DUO-ANGLUCIDTestosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalTestosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates